+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Forecast 2024-2030- Product Image
Global Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Forecast 2024-2030- Product Image
Sale

Global Ankylosing Spondylitis Market by Drug (Cimzia, Cosentyx, Enbrel), Type of Molecule (Biologics, Small Molecules), Mechanism Of Action, Route Of Administration, Dosage Forms, End User - Forecast 2024-2030

  • PDF Icon

    Report

  • 193 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5292911
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Ankylosing Spondylitis Market size was estimated at USD 5.18 billion in 2023, USD 5.60 billion in 2024, and is expected to grow at a CAGR of 8.31% to reach USD 9.06 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Ankylosing Spondylitis Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Ankylosing Spondylitis Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Ankylosing Spondylitis Market, highlighting leading vendors and their innovative profiles. These include Biothera Pharmaceuticals, Inc. by HiberCell, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Celltrion Healthcare Co.,Ltd., Eisai Co., Ltd, Eli Lilly and Company, Hetero Drugs Limited, Novartis AG, Reliance Life Sciences, Samsung Bioepis Co., Ltd., Sandoz International GmbH, Sanofi-Aventis Groupe S.A., Shanghai Pharmaceuticals Holding Co., Ltd., Trinity Biotech PLC, and Xian Janssen Pharmaceutical Ltd.

Market Segmentation & Coverage

This research report categorizes the Ankylosing Spondylitis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Cimzia
    • Cosentyx
    • Enbrel
    • Humira
    • Remicade
    • Simponi
  • Type of Molecule
    • Biologics
    • Small Molecules
  • Mechanism Of Action
    • Cyclooxygenase Inhibitors
    • Tumor Necrosis Factor Inhibitors
  • Route Of Administration
    • Oral
    • Parenteral
  • Dosage Forms
    • Liquid
    • Solid
  • End User
    • Clinics
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Ankylosing Spondylitis Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Ankylosing Spondylitis Market?
  3. What are the technology trends and regulatory frameworks in the Ankylosing Spondylitis Market?
  4. What is the market share of the leading vendors in the Ankylosing Spondylitis Market?
  5. Which modes and strategic moves are suitable for entering the Ankylosing Spondylitis Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Ankylosing Spondylitis Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidences of ankylosing spondylitis
5.1.1.2. Growing awareness about diagnostics and treatments for the disease
5.1.1.3. Rising number of orthopedic hospitals and diagnostic centers
5.1.2. Restraints
5.1.2.1. High cost of treatment and dearth of skilled surgeons and physiotherapists
5.1.3. Opportunities
5.1.3.1. Acceleration in research and development expenditure for the treatment of the spondylitis
5.1.3.2. The emergence of biologics for treating ankylosing spondylitis
5.1.4. Challenges
5.1.4.1. Concerns related to patent expiration of already approved drugs
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Ankylosing Spondylitis Market, by Drug
6.1. Introduction
6.2. Cimzia
6.3. Cosentyx
6.4. Enbrel
6.5. Humira
6.6. Remicade
6.7. Simponi
7. Ankylosing Spondylitis Market, by Type of Molecule
7.1. Introduction
7.2. Biologics
7.3. Small Molecules
8. Ankylosing Spondylitis Market, by Mechanism Of Action
8.1. Introduction
8.2. Cyclooxygenase Inhibitors
8.3. Tumor Necrosis Factor Inhibitors
9. Ankylosing Spondylitis Market, by Route Of Administration
9.1. Introduction
9.2. Oral
9.3. Parenteral
10. Ankylosing Spondylitis Market, by Dosage Forms
10.1. Introduction
10.2. Liquid
10.3. Solid
11. Ankylosing Spondylitis Market, by End User
11.1. Introduction
11.2. Clinics
11.3. Hospitals
12. Americas Ankylosing Spondylitis Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Ankylosing Spondylitis Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Ankylosing Spondylitis Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.2. Market Share Analysis, By Key Player
15.3. Competitive Scenario Analysis, By Key Player
16. Competitive Portfolio
16.1. Key Company Profiles
16.1.1. Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
16.1.2. Boehringer Ingelheim International GmbH
16.1.3. Bristol-Myers Squibb
16.1.4. Celltrion Healthcare Co.,Ltd.
16.1.5. Eisai Co., Ltd
16.1.6. Eli Lilly and Company
16.1.7. Hetero Drugs Limited
16.1.8. Novartis AG
16.1.9. Reliance Life Sciences
16.1.10. Samsung Bioepis Co., Ltd.
16.1.11. Sandoz International GmbH
16.1.12. Sanofi-Aventis Groupe S.A.
16.1.13. Shanghai Pharmaceuticals Holding Co., Ltd.
16.1.14. Trinity Biotech PLC
16.1.15. Xian Janssen Pharmaceutical Ltd
16.2. Key Product Portfolio
17. Appendix
17.1. Discussion Guide
17.2. License & Pricing
List of Figures
FIGURE 1. ANKYLOSING SPONDYLITIS MARKET RESEARCH PROCESS
FIGURE 2. ANKYLOSING SPONDYLITIS MARKET SIZE, 2023 VS 2030
FIGURE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. ANKYLOSING SPONDYLITIS MARKET DYNAMICS
FIGURE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
FIGURE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2030 (%)
FIGURE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2030 (%)
FIGURE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
FIGURE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 22. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 27. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 28. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
List of Tables
TABLE 1. ANKYLOSING SPONDYLITIS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. ANKYLOSING SPONDYLITIS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL ANKYLOSING SPONDYLITIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 6. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CIMZIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. ANKYLOSING SPONDYLITIS MARKET SIZE, BY COSENTYX, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ENBREL, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HUMIRA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. ANKYLOSING SPONDYLITIS MARKET SIZE, BY REMICADE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SIMPONI, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 13. ANKYLOSING SPONDYLITIS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 16. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CYCLOOXYGENASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. ANKYLOSING SPONDYLITIS MARKET SIZE, BY TUMOR NECROSIS FACTOR INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 19. ANKYLOSING SPONDYLITIS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. ANKYLOSING SPONDYLITIS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 22. ANKYLOSING SPONDYLITIS MARKET SIZE, BY LIQUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. ANKYLOSING SPONDYLITIS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 25. ANKYLOSING SPONDYLITIS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. ANKYLOSING SPONDYLITIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 47. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 48. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 51. CANADA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 52. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 53. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 54. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 55. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 56. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 63. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 64. UNITED STATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 68. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 69. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 70. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 71. ASIA-PACIFIC ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 73. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 74. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 75. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 76. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 77. AUSTRALIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 79. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 80. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 81. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 83. CHINA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 85. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 86. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 87. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 89. INDIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 91. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 92. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 94. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 95. INDONESIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 97. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 98. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 99. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 100. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 101. JAPAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 103. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 104. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 105. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 106. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 107. MALAYSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 109. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 110. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 113. PHILIPPINES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 114. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 115. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 116. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 117. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 118. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 119. SINGAPORE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 120. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 121. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 122. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 124. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 125. SOUTH KOREA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 126. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 127. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 128. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 129. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 131. TAIWAN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 133. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 134. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 136. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 137. THAILAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 139. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 140. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 141. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 142. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 143. VIETNAM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 151. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 152. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 153. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 154. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 155. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. DENMARK ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 158. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 159. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 160. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 161. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 162. EGYPT ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 163. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 164. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 165. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 166. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 167. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 168. FINLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 170. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 171. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 172. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 174. FRANCE ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 175. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 176. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 177. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 178. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 180. GERMANY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 182. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 183. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 184. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 185. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 186. ISRAEL ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 188. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 189. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 190. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 191. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 192. ITALY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 200. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 201. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 202. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 204. NIGERIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 206. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 207. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 208. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 209. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 210. NORWAY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 211. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 212. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 213. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 214. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 215. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 216. POLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 217. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 218. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 219. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 220. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 222. QATAR ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 224. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 225. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 226. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 227. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 228. RUSSIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 230. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 232. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 234. SAUDI ARABIA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 235. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 236. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 238. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 240. SOUTH AFRICA ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 241. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 242. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 243. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 244. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 245. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 246. SPAIN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 247. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 248. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 249. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 250. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 251. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 252. SWEDEN ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 254. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 255. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 256. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 258. SWITZERLAND ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 260. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 261. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 262. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 263. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 264. TURKEY ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 271. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
TABLE 272. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY TYPE OF MOLECULE, 2018-2030 (USD MILLION)
TABLE 273. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 274. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 275. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 276. UNITED KINGDOM ANKYLOSING SPONDYLITIS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ANKYLOSING SPONDYLITIS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 278. ANKYLOSING SPONDYLITIS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 279. ANKYLOSING SPONDYLITIS MARKET LICENSE & PRICING

Companies Mentioned

  • Biothera Pharmaceuticals, Inc. by HiberCell, Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Celltrion Healthcare Co.,Ltd.
  • Eisai Co., Ltd
  • Eli Lilly and Company
  • Hetero Drugs Limited
  • Novartis AG
  • Reliance Life Sciences
  • Samsung Bioepis Co., Ltd.
  • Sandoz International GmbH
  • Sanofi-Aventis Groupe S.A.
  • Shanghai Pharmaceuticals Holding Co., Ltd.
  • Trinity Biotech PLC
  • Xian Janssen Pharmaceutical Ltd

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages193
PublishedMarch 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 5.6 Billion
Forecasted Market Value ( USD ) by 2030 $ 9.06 Billion
Compound Annual Growth Rate8.3%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Global Ankylosing Spondylitis Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis - Product Image

Global Ankylosing Spondylitis Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

  • Report
  • 182 Pages
  • Global
From
Global Ankylosing Spondylitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031 - Product Image

Global Ankylosing Spondylitis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023-2031

  • Report
  • 113 Pages
  • Global
From
Ankylosing Spondylitis Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030 - Product Image

Ankylosing Spondylitis Drugs Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2030

  • Report
  • 255 Pages
  • Global
From
Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030 - Product Image

Ankylosing Spondylitis Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030

  • Report
  • 150 Pages
  • Global
From
Ankylosing Spondylitis Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Ankylosing Spondylitis Treatment Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 81 Pages
  • Global
From

About the Ankylosing Spondylitis Drug Market

The Ankylosing Spondylitis Drug market is a subset of the larger Musculoskeletal Disorders Drugs market. Ankylosing Spondylitis is a chronic inflammatory disorder that affects the spine and other joints, and is characterized by pain and stiffness. Ankylosing Spondylitis Drugs are used to reduce inflammation and pain, and to improve mobility. These drugs are typically administered orally or by injection, and may include biologics, non-steroidal anti-inflammatory drugs (NSAIDs), and corticosteroids. The Ankylosing Spondylitis Drug market is highly competitive, with a number of large pharmaceutical companies offering products. Some of the major players in the market include AbbVie, Amgen, Pfizer, Janssen, and Novartis. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.